Secondary C805S Mutation in HER2 Gene Confers Acquired Resistance to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer

被引：0
|
作者：
Kosaka, Takayuki [1 ]
Endoh, Hideki [1 ]
Repellin, Claire [1 ]
Tanizaki, Junko [1 ]
Ercan, Dalia [1 ]
Capelletti, Marzia [1 ]
Jaenne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
HER2; NSCLC; Acquired resistance; Target therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI09.08
引用
收藏
页码：S296 / S296
页数：1
相关论文
共 50 条
  • [31] Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
    Koga, Takamasa
    Kobayashi, Yoshihisa
    Tomizawa, Kenji
    Suda, Kenichi
    Kosaka, Takayuki
    Sesumi, Yuichi
    Fujino, Toshio
    Nishino, Masaya
    Ohara, Shuta
    Chiba, Masato
    Shimoji, Masaki
    Takemoto, Toshiki
    Suzuki, Makoto
    Janne, Pasi A.
    Mitsudomi, Tetsuya
    LUNG CANCER, 2018, 126 : 72 - 79
  • [32] Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
    Meedendorp, Arenda D.
    ter Elst, Arja
    't Hart, Nils A.
    Groen, Harry J. M.
    Schuuring, Ed
    van der Wekken, Anthonie J.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [33] Inconsistency of HER2 Status Between Core Needle Biopsy and Surgical Specimens: Focus on HER2 Null, HER2 Ultralow, and HER2 Low
    Wu, Si
    Liu, Hongbo
    Liu, Yueping
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [34] Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers.
    Li, Bob T.
    Zheng, Tao
    Ni, Ai
    Hellmann, Matthew David
    Jordan, Emmet
    Barron, David
    Smyth, Lillian Mary
    Solit, David B.
    Zehir, Ahmet
    Ross, Dara S.
    Berger, Michael F.
    Ladanyi, Marc
    Rudin, Charles M.
    Kris, Mark G.
    Arcila, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [36] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [37] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [38] Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
    Wang, Xin-Yu
    Zheng, Zhi-Xue
    Sun, Yu
    Bai, Yan-Hua
    Shi, Yun-Fei
    Zhou, Li-Xin
    Yao, Yun-Feng
    Wu, Ai-Wen
    Cao, Deng-Feng
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (04) : 335 - 347
  • [39] Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
    Xin-Yu Wang
    Zhi-Xue Zheng
    Yu Sun
    Yan-Hua Bai
    Yun-Fei Shi
    Li-Xin Zhou
    Yun-Feng Yao
    Ai-Wen Wu
    Deng-Feng Cao
    World Journal of Gastrointestinal Oncology, 2019, 11 (04) : 335 - 347
  • [40] Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer
    Cresti, Nicola
    Lee, Joanne
    Rourke, Emma
    Televantou, Despina
    Jamieson, David
    Verrill, Mark
    Boddy, Alan V.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : 27 - 37
12345